ImageneBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-10
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-09-30 was 0.00%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-06-30 was 0.00%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-09-30 was 0.00%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-10 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-10 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-07 | 0.00% 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | 0.00% 10-Q · filed 2025-07-24 | 0.00% 10-Q · filed 2025-07-24 | ||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-06 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-07 | 0.00% 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-08 | 0.00% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-12 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-09 | 0.00% 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-10 | 0.00% 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-14 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-07 | 0.00% 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-11 | 0.00% 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-17 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-10 | 0.00% 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 0.00% 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |